Latest news

• Antibiotics among 7 new drugs backed by EMA

  Other new drugs backed by the CHMP include Merck &Co's Dutrebis (lamivudine/raltegravir), another addition to the growing list of combination regimens for HIV.

• A new option for people with HIV

  Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... Raltegravir has since been launched in several countries worldwide for use in combination with other

• FDA clears Isentress formulation for infants with HIV

  The approval covers the use of this Isentress (raltegravir) formulation in children as young as four weeks of age who weigh at least 3kg.

• ViiV's Tivicay for HIV on course for EU approval

  Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year

• ViiV gets US nod for HIV drug dolutegravir

  a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients.